UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007866
Receipt number R000009239
Scientific Title The safety and efficacy of tocilizumab in patients with neuromyelitis optica: Multicenter Study
Date of disclosure of the study information 2012/05/01
Last modified on 2016/06/30 13:36:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The safety and efficacy of tocilizumab in patients with neuromyelitis optica: Multicenter Study

Acronym

Tocilizumab in patients with neuromyelitis optica: Multicenter Study

Scientific Title

The safety and efficacy of tocilizumab in patients with neuromyelitis optica: Multicenter Study

Scientific Title:Acronym

Tocilizumab in patients with neuromyelitis optica: Multicenter Study

Region

Japan


Condition

Condition

neuromyelitis optica

Classification by specialty

Neurology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to evaluate safety and efficacy of anti-IL-6R antibody tocilizumab in intractable neuromyelitis optica and to explore its mechanism of action.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

-Adverse events up to 2 years
-MRI lesion parameters, relapsing rate, and EDSS up to 2 years

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 6 years.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >=

Gender

Male and Female

Key inclusion criteria

Diagnosis of neuromyelitis optica (NMO), as defined by 2006 criteria published in NEUROLOGY vol. 66 or NMO seropositive spectrum disorder (recurrent optic neuritis or longitudinally extensive transverse myelitis). All patients must be anti-aquaporin 4 antibody seropositive.

Patients with intractable NMO who are resistant to the standard therapy or experiencing sever adverse reactions of the current therapy.

History of at least one relapse during the 1 year prior to initiation of this study.

Provision of written informed consent to participate in this study.

Key exclusion criteria

1) Patients with severe infection such as tuberculosis, pneumocystis carinii pneumonia, nontuberculous mycobacterial infection, hepatitis B, hepatitis C, or chronic active EB virus infection.
2) Patients with a history of tuberculosis infection or patients with pleural thickness or old tuberculin in chest X-ray.
3) Patients with a history of hypersensitivity to this drug.
4) Patients with a history of intestinal diverticulum.
5) Patients with interstitial pneumonitis.
6) Patients with leukopenia (white blood cell number < 4000/mm3), lymphopenia (lymphocyte number < 1000/mm3) or seropositivity for beta-D-glucan in peripheral blood.
7) Pregnant women or patients with possible pregnancy.
8) Patients who can not provide consent to participate in this study by themselves.
9) Patients whose EDSS are more than 7.

Target sample size

15


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takashi Yamamura

Organization

National Institute of Neuroscience, NCNP

Division name

Department of Immunology

Zip code


Address

4-1-1, Ogawahigashi, Kodaira, Tokyo 187-8502, Japan

TEL

042-341-2711

Email

yamamura@ncnp.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Takashi Yamamura

Organization

National Institute of Neuroscience, NCNP

Division name

Department of Immunology

Zip code


Address

4-1-1, Ogawahigashi, Kodaira, Tokyo 187-8502, Japan

TEL

042-341-2711

Homepage URL


Email

yamamura@ncnp.go.jp


Sponsor or person

Institute

Department of Immunology, National Institute of Neuroscience, NCNP

Institute

Department

Personal name



Funding Source

Organization

Ministry of Health, Labour and Welfare

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Department of Neurology, Kinki University Faculty of Mediceine

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 05 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2011 Year 09 Month 30 Day

Date of IRB


Anticipated trial start date

2012 Year 05 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 04 Month 30 Day

Last modified on

2016 Year 06 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009239


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name